Drug-eluting stents: The end of restenosis?

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 4, 2004, Pages 423-431

  Wong, A ^a   Chan, Charles ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

Coronary angioplasty; Paclitaxel; Sirolimus

Indexed keywords

ABT 578; ANGIOPEPTIN; ANTIMITOTIC AGENT; BATIMASTAT; CORTICOSTEROID; DACTINOMYCIN; ESTRADIOL; EVEROLIMUS; HIRUDIN; ILOPROST; METHYLRAPAMYCIN; MYCOPHENOLIC ACID; PACLITAXEL; POLYMER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TRANILAST; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; ARTERY LESION; BARE METAL STENT; CLINICAL TRIAL; COMPLEX CORONARY ARTERY LESION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; DRUG RELEASE; ENDOPROSTHESIS LOOSENING; HEALTH CARE COST; HEALTH CARE FINANCING; HEART MUSCLE REVASCULARIZATION; HUMAN; IN STENT RESTENOSIS; INCOMPLETE STENT APPOSITION; INTERMETHOD COMPARISON; LEGAL ASPECT; MATERIAL COATING; MEDICAL ETHICS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; SAFETY; SLOW RELEASE FORMULATION; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; THROMBOSIS;

EID: 4644226291     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Pocock SJ, Henderson RA, Rickards AF, Hampton JR, King SB 3rd, Hamm CW, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184-9.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994:331:489-95.
3. The Bypass Angioplasty Revascularization Investigation (BAR) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996:335:217-25.
4. Legrand VM, Serruys PW, Unger F, Van Hout BA, Vrolix MC, Fransen GM, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 2004;109:1114-20
5. Lim VY, Chan CN. Prevention of restenosis after percutaneous coronary intervention: the continuing challenge. Ann Acad Med Singapore 2002;31:102-6
6. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
8. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996;94:35-43.
9. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54.
10. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499-506.
11. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
12. Schwartz RS, Henry TD. Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med 2003;3(suppl 5):S4-S9
13. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-703.
14. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
15. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
16. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-76.
17. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
18. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomised comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
19. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
20. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5
21. Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45.
22. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomised study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
23. Knopf W. DELIVER I: A US multicenter, randomised, single-blind study of the ACHIEVE drug coated coronary system. Presented at: Transcatheter Cardiovascular Therapeutic; 2003 Sept 16-21; Washington DC. Available at: http://www.tctmd.com/expert-presentations/multi-slide.html?product_id=5302. Accessed July 14, 2004.
24. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-93.
25. Grube E, Hauptmann K, Colombo A, DiSciascio G, Silber S, Bach R, et al. SCORE trial interim safety results: despite efficacy, late stent thrombosis with the QuaDDS-QP2 stent [abstract]. J Am Coll Cardiol 2002;39(suppl A):38A.
26. Costa R, Lansky A, Mehran R, Tsuchiya Y, Cristea E, Negoita M, et al. Everolimus-eluting stent for the treatment of de novo coronary lesion: An angiographic follow-up of the FUTURE trial [abstract]. Am J Cardiol 2003:92(suppl 1);61L.
27. Meredith I. ENDEAVOR I: 4-month angiographic and IVUS result. Presented at: Transcatheter Cardiovascular Therapeutic; 2003 Sept 16-21; Washington DC. Available at: http://www.tctmd.com/expert-presentations/multi-slide.html? product_id=5356. Accessed July 14, 2004.
28. Robinson K, Chronos N, Royal J, Suh L, Cipolla GD, Virmani R, et al. Actinomycin-D drug eluting stents perserve lumen size and inhibit fibrocellular neointima in pig coronary arteries [abstract]. Circulation 2001;104(suppl 11):506.
29. Serruys PW. Final ACTION results: Actinomycin Eluting stents improves outcomes by reducing neointimal hyperplasia. Presented at Transcatheter Cardiovascular Therapeutic; 2002 Sept 24-29; Washington DC. Available at: http://www.tctmd.com/expert-presentations/multi-slide.html? product_id=3801. Accessed July 14, 2004.
30. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004:109:190-5.
31. Abizaid AC. WISDOM Registry update. Presented at Transcatheter Cardiovascular Therapeutic; 2003 Sept 16-21; Washington DC. Available at: http://www.tctmd.com/expert-presentations/multi-slide.html? product_id=5206. Accessed July 14, 2004.
32. Colombo A. Updates from international registries: The Milan Complex Lesion Registry. Presented at Transcatheter Cardiovascular Therapeutic, 2003 September 16-21, Washington DC. Available at: http:// www.tctmd.com/expert- presentations/multi-slide.html? product_id=6026. Accessed July 14, 2004.
33. Kerner A, Gruberg L, Kapeliovich M, Grenadier E. Late stent thrombosis after implantation of a sirolimus-eluting stent. Cathet Cardiovasc Interv 2003;60:505-8.
34. FDA public health web notification: Information for physicians on sub-acute thrombosis (SAT) and hypersensitivity reactions with the use of the Cordis CYPHER™ coronary stent. US: Food and Drug Administration. 2003. Available at: http://www.fda.gov/cdrh/safety/cypher.html. Accessed March 12, 2004.
35. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
36. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, et al. Intravascular ultrasound findings in the multicenter, randomised, double-blind RAVEL (RAndomised study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
37. Abizaid A. Updates from the FIM experience: Are the results durable? Presented at Transcatheter Cardiovascular Therapeutic; 2003 Sept 16-21; Washington DC. Available at: http://www.tctmd.com/expert-presentations/multi- slide.html? product_id=6014. Accessed July 14, 2004.
38. Morice MC. RAVEL 2-year follow-up. Presented at Transcatheter Cardiovascular Therapeutic; 2003 Sept 16-21; Washington DC. Available at: http: //www.tctmd.com/expert-presentations/multi-slide.html? product_id=6018. Accessed July 14, 2004.
39. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomised trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-40.
40. Waksman R, Ajani AE, White RL, Chan R, Bass B, Pichard AD, et al. Five-year follow-up after intracoronary gamma radiation therapy for instent restenosis. Circulation 2004;109:340-4.
41. Cohen DJ, Bakhai A, Shi C, Githiora L, Berezin RH, Caputo R, et al. Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenosis: results from the randomised SIRIUS trial [abstract]. J Am Coll Cardiol 2003;41(suppl):32A
42. Kong DF, Eisenstein EL, Sketch MH Jr, Zidar JP, Ryan TJ, Harrington RA, et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J 2000;147:449-56
43. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43:513-8.
44. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, et al. Randomised study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109:1244-9
45. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003;107:2178-80.